Upadacitinib As a Novel Treatment for Refractory Eyelid Dermatitis

Northwestern University

Status and phase

Not yet enrolling

Early Phase 1

Conditions

Eyelid Dermatitis

Treatments

Drug: Upadacitinib 15 MG

Study type

Interventional

Funder types

Other

Identifiers

STU00221561

Details and patient eligibility

About

This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.

Enrollment

10 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Individuals age 18-70 years old with eyelid dermatitis for at least two months
Failure of at least one topical prescription cream for the eyelid dermatitis (steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib)
Women of reproductive potential must agree to using effective contraception during treatment and for 4 weeks following the final dose of Upadacitinib.
Willing and able participants that provide informed consent
Willing and able participants that comply with study activities

Exclusion criteria

Self-reported history of allergic response to upadacitinib
Subject with self-reported history of heart disease, stroke, or neurological conditions
Currently taking topical medications for eyelid dermatitis within one week of starting study drug
Women who are pregnant, nursing, or who may become pregnant during the study
Non-English-speaking subjects
Patients with an active serious infection
Patients with active TB or latent TB, patients should be tested for TB prior to upadacitinib treatment.
Patients with active HBV/HCV or abnormal lab ranges, Lab Data: Hb<8g/dL, ALC<500 cells/mm3 and ANC <1000 cells/mm3
Patients with a history of malignancy within the last 5 years other than successfully treated NMSC.